Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Cannabinoid Receptor Agonists" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.
Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
The present application describes a method of treating pain with a combination of a CB2 cannabinoid receptor agonist and rimonabast.
Owner:ABBVIE INC
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
InactiveUS20080261922A1Preventing and ameliorating sleep-related breathing disorderBiocideNervous disorderNorepinephrine reuptake inhibitorPhosphate
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
InactiveUS20080103209A1Extended half-lifeBiocideNervous disorderCannabinoid Receptor AgonistsAgonist
Compositions and methods for treating noninflammatory pain, including but not limited to, neuropathic pain by using peroxisome proliferator activated receptor a (PPARa) agonists to treat a subject having such pain are described. The agonists may be used with additional therapeutic agents such as an inhibitor of fatty acid amide hydrolase or a cannabinoid CB1 or CB2 cannabinoid receptor agonist.
Owner:RGT UNIV OF CALIFORNIA
Imine compound
InactiveCN101065125AHas cannabinoid receptor agonismNervous disorderOrganic chemistryCannabinoid Receptor AgonistsImine
An imine compound represented by the formula (I) (wherein A represents a heterocyclic group; R<1>, R<2>, and R<3> each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkoxy, etc.; R<4> represents optionally substituted C1-10 alkyl, C2-6 alkenyl, or aryl; R<5> represents hydrogen, C1-10 alkoxy, C1-6 haloalkyl, optionally substituted C1-10 alkyl or C2-6 alkenyl, optionally substituted aryl or heterocyclic group, etc.; and W represents -CO-, -CO-CO-, -CO-NH-, -CS-NH-, or -SO2-) or a cannabinoid receptor agonist containing the compound as an active ingredient. The imine compound has agonistic activity against a cannabinoid receptor and is useful as a therapeutic or preventive agent for pains and autoimmune diseases.
Owner:TAISHO PHARMACEUTICAL CO LTD
Treatment of gastroesophageal reflux disease
InactiveUS7358245B2Improve concentrationBiocideOrganic chemistryCannabinoid Receptor AgonistsSphincter of Oddi
The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.
Owner:ASTRAZENECA AB
Peripherally-acting cannabinoid receptor agonists for chronic pain
ActiveUS9656981B2Organic active ingredientsOrganic chemistryChronic painCannabinoid Receptor Agonists
Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.
Owner:RGT UNIV OF CALIFORNIA
Methods of treatment of inflammation of the gut
InactiveUS20170112787A1Improving immune homeostasisRelieve symptomsPharmaceutical delivery mechanismAmide active ingredientsDiseaseAutoimmune disease
Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include Anandamide. The methods are particularly useful to treat gut inflammation associated with diabetes mellitus Type I.
Owner:UNIV OF CONNECTICUT
Composition
InactiveUS20090311227A1Good effectReduce dosageBiocideOrganic active ingredientsMetaboliteCannabinoid Receptor Agonists
The present invention relates to a composition comprising: i) at least one strain of a Lactobacillus sp and / or a metabolite thereof; and ii) a cannabinoid receptor agonist and / or a opioid receptor agonist. In addition, the present invention relates to methods using and uses of such a composition.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
InactiveCN101489548AAmide active ingredientsCardiovascular disorderCannabinoid Receptor AgonistsHypothermia induced
The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.
Owner:纽若科伊公司
Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.
Owner:WYLDER NATION FOUND
Compositions and methods for enhancing immune response to vaccination and improving vaccine production
PendingUS20200215185A1Enhance immune responseIncrease virus yieldSsRNA viruses negative-senseCosmetic preparationsVaccinationMiltefosine
Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and / or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and / or to improve sensitivity of cell-based virus assays.
Owner:VERSITECH LTD
Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Application of II type cannabinoid receptor stimulant in preparation of medicine for treating newborn cerebral hemorrhage
InactiveCN105640934APromote nerve regenerationPromote differentiationNervous disorderTetracycline active ingredientsStimulantNeonatal cerebral hemorrhage
The invention relates to the field of medicine for treating newborn cerebral hemorrhage, in particular to application of II type cannabinoid receptor stimulant in preparation of medicine for treating newborn cerebral hemorrhage. The application of the II type cannabinoid receptor stimulant in preparation of medicine for promoting nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation after treating newborn cerebral hemorrhage is provided. It is found through tests that the II type cannabinoid receptor stimulant has the effects of promoting newborn nerve regeneration, neural precursor cell differentiation and neural stem cell proliferation; in addition, GMH-induced hydrocephalus can be remarkably reduced. In addition, the II type cannabinoid receptor stimulant is used in cooperation with minocyline which can remarkably increase transmittance of the blood brain barrier of the II type cannabinoid receptor stimulant and add the anti-inflammation effect treatment effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Novel use of cannabinoid receptor agonist
An inhibitor for inflammatory cellular infiltration in the respiratory tract, inhibitor for hyperirritability in the respiratory tract, muciparous inhibitor, or bronchodilator which contains as an active ingredient a compound selected from the group of compounds represented by the formulae (I) and (II).
Owner:SHIONOGI & CO LTD
5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists
The invention is directed to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor agonists, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, administered to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors.Compounds of the present invention include compounds of formula (I):wherein the substituents have the definitions given in the specification.
Owner:SOLVAY PHARM BV
Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
InactiveUS20090318526A1Induce hypothermiaBiocideOrganic chemistryCannabinoid Receptor AgonistsHypothermia induced
The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.
Owner:NEUROKEY
Novel cannabinoid receptor cb2 ligand 4-(aminomethyl)-n,n-dialkylanilines
ActiveUS20180141902A1Modulate activityOrganic chemistrySkeletal disorderCannabinoid Receptor CB2Cannabinoid receptor
Disclosed herein are novel cannabinoid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
Owner:UNIVERSITY OF PITTSBURGH
Cannabinoid receptor CB2 ligand 4-(aminomethyl)-N,N-dialkylanilines
ActiveUS10696624B2Organic chemistrySkeletal disorderCannabinoid Receptor CB2Cannabinoid Receptor Agonists
Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
Owner:UNIVERSITY OF PITTSBURGH
Peripherally-acting cannabinoid receptor agonists for chronic pain
Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.
Owner:RGT UNIV OF CALIFORNIA
Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
ActiveUS20200253947A1Improve treatment outcomesReduce dosageNervous disorderHydroxy compound active ingredientsSerine hydrolaseHydrolase inhibitor
Owner:MEDIPURE PHARMA INC
Preparation method and application of oligodendroglia cells
The invention provides a preparation method and application of oligodendroglia cells. The provided regimen reproduces the major step of oligodendrocyte differentiation in a time that is significantly shorter than 75-95 days required for previous regimens. The NSC differentiation is induced through a cannabinoid receptor agonist WIN55212-2, and the induction of OLIG2 + OPC is promoted. The WIN-derived OLIG2 + progenitor cells are differentiated into PDGFR alpha + OPCs, have high mobility, and can be further differentiated into mature OL with strong myelination ability. When the WIN-derived OPC is transplanted to a diseased region, the athletic ability of a spinal cord injury (SCI) mouse is significantly improved from the second week after transplantation. Immunostaining results show that the WIN-derived OPC can be differentiated into mature OL, so that damaged axons are myelinated. The method and the product disclosed by the invention are widely applied to the field of cell therapy, and particularly have a remarkable treatment effect on spinal cord injury.
Owner:深圳市夏同生物医药科技有限公司
Combination therapy for reducing side effects using cannabinoid receptor ligands
The present application describes a method of treating conditions treatable with a CB2 cannabinoid receptor agonist with reduced CB1-mediated side effects using a combination therapy comprising a CB2 agonist and a CB1 ligand, which can be a CB1 antagonist or a CB1 inverse agonist.
Owner:ABBVIE INC
Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
Owner:MEDIPUR PHARM CORP
Method and kit for regulation of microvascular tone
Methods and kits for regulating arterial microvascular tone in which a COX-2 inhibitor and a cannabinoid receptor agonist are co-administered to a subject.
Owner:MOORE BOB M II
Application of cannabinoid receptor drug in preparation of drug for treating myocardial cell necrosis apoptosis
InactiveCN112007156AImprove pathological changesObvious fibrosisPharmaceutical active ingredientsCardiovascular disorderAtypical antipsychoticQuetiapine
The invention belongs to the field of biological medicines, and relates to a new application of a cannabinoid receptor drug, in particular to an application of a cannabinoid receptor type 1 (CB1R) antagonist and a cannabinoid receptor type 2 (CB2R) agonist in preparation of a drug for treating myocardial cell necrotic apoptosis. The invention also provides a corresponding kit. Quetiapine is a common atypical antipsychotic and is used for treating schizophrenia, bipolar affective disorder, severe depression and other mental disorders. Experiments prove that quetiapine promotes inflammatory infiltration and fibrosis reconstruction of myocardial cells; quetiapine has the effect of promoting RIP3 and MLKL and activates a myocardial cell necrotic apoptosis pathway, and the cannabinoid receptortype 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist can significantly inhibit the necrotic apoptosis pathway, so the cannabinoid receptor type 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist are used for treating quetiapine cardiotoxicity. The invention provides a novel application of the cannabinoid receptor type 1 (CB1R) antagonist and the cannabinoid receptor type 2 (CB2R) agonist, and provides novel reference data for development of myocardial cytotoxicity treatment drugs.
Owner:FUDAN UNIV
Application of type-II cannabinoid receptor agonist in preparation of drugs for treating hypertensive cerebral hemorrhage
InactiveCN105663113APrevent proliferationInhibitory activityNervous disorderTetracycline active ingredientsInjury brainBlood brain barrier penetration
The invention relates to the field of cerebral hemorrhage drugs, in particular to application of type-II cannabinoid receptor agonist in the preparation of drugs for inhibiting microglial cell proliferation and treating hypertensive cerebral hemorrhage after the treatment of hypertensive cerebral hemorrhage.In-vivo experiments show that the type-II cannabinoid receptor agonist is capable of inhibiting microglial cell proliferation and activation after cerebral hemorrhage, inhibiting perihematomal neurogenic inflammations and improving secondary brain injury caused by cerebral hemorrhage; in addition, in the use with the type-II cannabinoid receptor agonist, minocycline is capable of significantly increasing blood brain barrier penetration rate of the type-II cannabinoid receptor agonist and improving anti-inflammatory therapeutic effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Applications of CB2R (cannabinoid receptor 2) agonist in preparing medicines for treating hypertensive cerebral hemorrhage
InactiveCN105709226AReduce the degree of edemaPrevent brain atrophyNervous disorderTetracycline active ingredientsCannabinoid receptorCerebral hemorrhages
The invention relates to the field of cerebral hemorrhage drugs, in particular to the application of type II cannabinoid receptor agonists in the preparation of drugs for the recovery of neurological function and brain atrophy after hypertensive cerebral hemorrhage. The invention provides the application of a type II cannabinoid receptor agonist in the preparation of a drug for the recovery of neurological function and cerebral edema after hypertensive cerebral hemorrhage. The present invention finds through in vivo experiments that the type II cannabinoid receptor agonist can reduce the degree of brain tissue edema induced by autologous blood and prevent brain atrophy; the use of the drug after hypertensive cerebral hemorrhage can significantly improve neurological function recovery. In addition, the type II cannabinoid receptor agonist is used in combination with minocycline, and the minocycline can significantly increase the blood-brain barrier penetration rate of the type II cannabinoid receptor agonist, and increase the therapeutic effect of anti-inflammatory effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
InactiveUS20200253948A1Improve treatment outcomesReduce dosageNervous disorderHydroxy compound active ingredientsSerine hydrolaseHydrolase inhibitor
Owner:MEDIPURE PHARMA INC
Application of compound as or in preparation of cannabinoid receptor agonist or antagonists
PendingCN111789860AImprove immunityRegulate neurastheniaOrganic active ingredientsNervous disorderAntagonismType i receptor
The invention relates to discovery and application of a cannabinoid receptor new agonist and three new antagonists. The agonist is Kfb77, and the antagonists are Kfb28, Kfb68 and Kga1. In-vitro cell experiments show that the compound Kfb77 has an excitation effect on a cannabinoid type I receptor (CB1), the compound Kga1 has an antagonism effect on CB1, the compound Kfb28 has an antagonism effecton a cannabinoid type II receptor (CB2), and the compound Kfb68 has an antagonism effect on CB1 and CB2. Accordingly, the new natural agonist and antagonists for the CB1 and the CB2 provided by the invention provide candidate compounds for research and development of drugs for treating neurodegenerative diseases such as psychotic diseases, obesity / metabolic disorder related diseases, immune systemregulation and multiple sclerosis.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
A cannabinoid receptor 2 (cb2) agonist
Owner:CHENGDU UNIVERSITY OF TECHNOLOGY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com